Filing Flows › Castle Biosciences (CSTL) › Q1 2026
Castle Biosciences (CSTL) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 6, 2026
Castle Biosciences (CSTL) reported revenue of $83.7M for the first quarter 2026 (Q1 2026), -5% from a year earlier and -4% from the quarter before. Operating margin was -22.0%, net loss $14.5M (17.4% of revenue).
Castle Biosciences, Q1 2026: revenue $83.7M (-5% year over year), operating margin -22.0%, net loss $14.5M, operating cash flow −$22.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $83.7M | -4% | -5% |
| Operating profit | −$18.4M | — | — |
| Net earnings | −$14.5M | — | — |
| Operating cash flow | −$22.1M | -182% | — |
What changed
Revenue was $83.7M in Q1 2026, down 5% year over year and down 4% from the previous quarter. Non-Dermatologic was the largest line at 51% of revenue. Dermatologic lost $21.9M year over year (down 35%), 507% of the total change.
Operating costs exceeded revenue by $18.4M, an operating margin of -22.0%. Total costs fell 12% while revenue fell 5%. The fastest-growing cost line was Cost of revenue (+25%). The quarter ended with a net loss of $14.5M, wider than the previous quarter's $2.3M loss. Non-operating items added $4.0M, -28% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$22.1M. Non-cash charges added back $3.9M of depreciation and amortization and $9.8M of share-based compensation. Working capital and other items used $21.3M. Capital expenditures of $12.5M exceeded it, leaving free cash flow of −$34.6M.
Questions
What was Castle Biosciences' revenue in the first quarter 2026?
Castle Biosciences (CSTL) reported revenue of $83.7M for the first quarter 2026 (Q1 2026), -5% from a year earlier and -4% from the quarter before.
Was Castle Biosciences profitable in the first quarter 2026?
Operating loss was $18.4M (-22.0% of revenue) and net loss $14.5M.
Source: Castle Biosciences 10-Q on SEC EDGAR.